Turner Pope Investments - New Analysis Identifies Major AUD Breakthrough
Research on Solvonis Therapeutics Plc (SVNS:LON) from Turner Pope Investments
Solvonis Therapeutics plc announced that new analyses of its SVN-001 treatment for Alcohol Use Disorder (AUD) show a 67% reduction in heavy drinking days compared to placebo at weeks 17-20, a statistically significant result recognized by European regulators. Indirect cross-trial comparisons suggest SVN-001's efficacy in reducing heavy drinking days surpasses naltrexone and GLP-1 therapies like pemvidutide and semaglutide, with a more patient-friendly four-week dosing regimen. The company is advancing SVN-001 through UK Phase 3 trials with European expansion planned, targeting an estimated 12.5 million people with severe AUD in the UK and EU4, and is developing SVN-002 for the US market.
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
